The Pipeline

Home>News>The Pipeline

Cartherics executes Option Agreement with The Ohio State University

TISSUE FACTOR AS A NOVEL TARGET FOR CAR-NK CELLS

Melbourne, Australia, 20 March 2024 –  Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing immune cell therapies for the treatment of cancer, is pleased to announce that it has executed an option agreement to evaluate intellectual property (IP) from The Ohio State University (Ohio […]

2024-03-20T12:56:13+11:00March 20th, 2024|

Cartherics: Leading the Charge in Immunotherapy for Solid Tumours

At Emergence 2024, Cartherics’ COO, Dr Ian Nisbet was interviewed by Wholesale Investor. In the interview, Ian discusses the company’s cutting-edge strategies in combating solid tumours through cell-based immunotherapy. From leveraging stem cells to navigating regulatory pathways and entering clinical trials, Cartherics is on a mission to redefine cancer treatment. This interview highlights the challenges, […]

2024-03-19T13:38:02+11:00March 19th, 2024|

Teal Ribbon Day: Raising awareness for ovarian cancer

Each year in Australia around 1815 women are diagnosed with ovarian cancer. In most cases the cancer will be diagnosed at an advanced stage, where it is very difficult to treat.

To help raise awareness for ovarian cancer, Cartherics hosted a Teal Ribbon Day afternoon tea. Our Teal Tea provided a great opportunity to bring people […]

2024-03-08T13:39:16+11:00February 28th, 2024|

Cartherics to present and exhibit at Emergence 2024

Cartherics is pleased to announce that it will be attending Emergence 2024 – The Era of Abundance investment conference at the Hilton Sydney next week.

The company’s CEO, Prof. Alan Trounson AO, will be presenting at 11:14 am on Wednesday 28th February. His presentation will discuss:

  • Cartherics’ breakthrough approach to treating solid tumours.
  • How CTH-401, […]
2024-02-22T15:57:01+11:00February 22nd, 2024|

Cartherics’ CEO discusses the future of solid tumour therapy

Cartherics’ CEO, Prof. Alan Trounson AO was recently interviewed by Wholesale Investor to discuss the company’s latest developments and the future of solid tumour therapy. In the interview Alan, shares insights into Cartherics’ cutting-edge technology, including the use of gene-edited natural killer (NK) cells and the strategic approach to leveraging a robust IP portfolio for […]

2024-02-15T15:18:52+11:00February 15th, 2024|

Ovarian cancer: Biotech company Cartherics to start human trials of new drug

There’s an urgent need for new treatment options for ovarian cancer patients who are often diagnosed at advanced stages when survival outcomes are worse. Cartherics’ lead cell therapy CTH-401 is a natural killer (NK) cell product designed to seek out and destroy the cells that cause ovarian cancer, with clinical trials planned for early next […]

2024-02-12T15:37:35+11:00February 12th, 2024|

Positive pre-IND meeting with US FDA for new ovarian cancer cell therapy

Melbourne, Australia, 1 February 2024 –  Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing immune cell therapies for the treatment of cancer, is pleased to announce that it has successfully completed a pre-investigational new drug (pre-IND) meeting with the US Food and Drug Administration (FDA) for a Phase I/II clinical trial of its […]

2024-02-01T15:38:56+11:00February 1st, 2024|

Chimeric Antigen Receptor (CAR) – Natural Killer (NK) Cells – Looking good for cancer therapy

As published in Drug Target Review

 Professor Alan Trounson, AO

Dr Huimin Cao

Dr Aleta Pupovac

The suitability of NK cells for cancer therapy has been challenged by some investor and business interests because of limited efficacy data from clinical trials, but is this really a valid belief at the present stage of development of the immune therapy […]

2023-11-28T15:36:13+11:00November 28th, 2023|

Rearming the body to fight cancer

Cartherics is currently undertaking a new capital raise to initiate clinical trials for its lead allogeneic cell therapy for ovarian cancer. CTH-401 is the only NK cell product currently under development that targets the adenocarcinoma specific antigen – TAG-72.

The company is looking to raise up to AU$20 million to support its ongoing development activities and […]

2023-11-15T16:28:45+11:00November 15th, 2023|

Importance of building Australia-China biotech collaborations

China is Australia’s greatest two-way trading partner in products and services, making up close to one-third of the nation’s international trade, as per the Australian Department of Foreign Affairs and Commerce. Resources and energy make up the largest share of Australia’s exports to China, with iron ore, natural gas and gold leading the way.

There are a number […]

2023-11-01T13:46:01+11:00November 1st, 2023|
Go to Top